ARA-290
Cibinetide — an 11-amino-acid peptide derived from EPO, researched for nerve protection and tissue repair without red-blood-cell stimulation.
What It Is
ARA-290, also known as cibinetide, is an 11-amino-acid peptide derived from erythropoietin (EPO). Unlike traditional EPO, ARA-290 was developed to investigate the tissue-protective and repair-related effects of EPO signaling without its primary red-blood-cell-stimulating activity.
ARA-290 works through the Innate Repair Receptor (IRR) pathway, involved in the body’s response to tissue injury and inflammation. Research has focused particularly on its potential ability to help regulate excessive inflammatory signaling while supporting nerve protection, tissue repair, and recovery.
Who May Benefit
- Nerve health and recovery research
- Neuropathic pain and nerve-related discomfort
- Small fiber neuropathy research
- Recovery following injury or surgery
- Chronic inflammatory conditions
- Tissue repair and regeneration
- Inflammation-related recovery
What to Expect
ARA-290 is generally researched as a recovery and nerve-support compound rather than something expected to produce an immediate effect. Research has investigated changes in nerve function, neuropathic symptoms, inflammatory signaling, and tissue recovery over time.
Some report improvements in burning, tingling, nerve discomfort, sensation, and overall recovery — these experiences are anecdotal. Response can vary considerably depending on the underlying condition, severity, duration of symptoms, and individual biology.
What to Pair It With
Reconstitution
Suggested Research Dosing Strategy
Administration Notes
Subcutaneous administration is commonly used in research protocols.
ARA-290 is generally researched as a systemic compound rather than requiring injection directly into an area of discomfort.
Consistency is important when evaluating longer-term recovery or nerve-related outcomes.
Research Considerations
One of ARA-290’s most interesting characteristics is that it was designed to investigate EPO’s tissue-protective signaling without intentionally reproducing its primary hematopoietic (red-blood-cell) effect.
Promising early research does not necessarily translate into predictable clinical results — ARA-290 is not an established treatment for neuropathy or chronic pain.
Have a specific question about ARA-290? Chat with Pulse, Signal IQ’s free AI research assistant — ask about mechanisms, stacking, or how it compares to other compounds.